Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-11
2009-10-27
Desai, Anand U (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S363000, C514S003100, C514S776000
Reexamination Certificate
active
07608692
ABSTRACT:
Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
REFERENCES:
patent: 4179337 (1979-12-01), Davis
patent: 4766106 (1988-08-01), Katre
patent: 5122614 (1992-06-01), Zalipsky
patent: 5214131 (1993-05-01), Sano et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 5747639 (1998-05-01), Seely
patent: 5824784 (1998-10-01), Kinstler
patent: 5839443 (1998-11-01), Rose et al.
patent: 6051557 (2000-04-01), Drucker et al.
patent: 6268343 (2001-07-01), Knudson et al.
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6376549 (2002-04-01), Fine et al.
patent: 6429197 (2002-08-01), Coolidge et al.
patent: 6451974 (2002-09-01), Hansen
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6723530 (2004-04-01), Drucker
patent: 6753165 (2004-06-01), Cox et al.
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: 6872700 (2005-03-01), Young et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 6982248 (2006-01-01), Coolidge et al.
patent: 7153825 (2006-12-01), Young et al.
patent: 7189690 (2007-03-01), Rosen et al.
patent: 7226990 (2007-06-01), Knudsen et al.
patent: 7238660 (2007-07-01), Rosen et al.
patent: 7259136 (2007-08-01), Hathaway et al.
patent: 7271149 (2007-09-01), Glaesner et al.
patent: 7307148 (2007-12-01), Bousquet-Gagnon et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 2002/0147131 (2002-10-01), Coolidge et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 2006/0030528 (2006-02-01), Hathaway et al.
patent: 2007/0037750 (2007-02-01), Young et al.
patent: 0619322 (1994-10-01), None
patent: WO 95/70989 (1995-03-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/43708 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 00/41548 (2000-07-01), None
patent: WO 00/66629 (2000-11-01), None
Yeh et al. (1992) Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate, Proc. Natl. Acad. Sci. U S A., vol. 89, No. 5, pp. 1904-1908.
Doyle et al. (2005) In vivo biological activity of exendin (1-30), Endocrine, vol. 27, No. 1, pp. 1-9.
Abuchowski, et al.; “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase”; Journal of Biological Chemistry; vol. 252; Issue 11;3582-3588 (Jun. 1977).
Chen, et al.; Diabetes, vol. 1, Suppl.1: A426, Abstract No. 1884 (May 1999).
Declaration of Andrew Young attached to Request for Inter Partes Reeaxmination of US Patent No. 6,924,264, 2007.
Declaration of John Herich attached to Request for Inter Partes Reeaxamination of US Patent No. 6,924,264, 2007.
England, et al.; “Determination of the Packed Cell Volume Using I-Human Serum Albumin”; British Journal of Hermatology, vol. 30; pp. 365-370 (Dec. 1974).
Gennaro et al, Remington: The Science and Practice of Pharmacy, 19th Ed., Mack Printing Company, Easton, PA, pp. 1457, 1461, 1526, 1550 (1995).
Giberman; “Determination of the Trapped Volume in a Pellet of Red Blood Cells”; Section of Biological Ultrastructure, The Weismann Institute of Science, Rehovot (Israel); Experimentia, 29: pp. 1083-1085; (Feb. 1973).
Gould; “Diabetes Mellitus in Cattle”; Veterinary Record; vol. 109; pp. 539 (Dec. 1981).
Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 53-137 (1988).
Maack, et al.; “Renal Fllatration, Transport, and Metabolism of Low-Molecular-Weight Proteins: A Review”; Kidney International; vol. 16; pp. 251-270 (Mar. 1979).
O'Hagen; “Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration”; J Pharma Pharmacol; vol. 49:pp. 1-10; (Sep. 1997).
Patentee Response to First Office Action issued by the United States Patent Office dated Jan. 17, 2008 for Inter Partes Reexamination of US Patent No. 6,924,264 ; (Apr. 2008).
Poznansky; “In Vitro and In Vivo Activity of Soluble Cross-Linked Uricase-Albumin Polymers: A Model for Enzyme Therapy”; Life Sciences; vol. 24:pp. 153-158; (1979).
Remy, et al.; “Immunogenicity and Antigenicity of Soluble Cross-Linked Ensyme/Albumin Polymers: Advantages for Enzyme Therapy”; The Lancet; vol. 2:pp. 68-70 (Jul. 1978).
Ruiz-Grande, et al.; Renal Catabolism of Human Glucagon-like Peptides 1 and 2; CAN. J. Physiol. Pharmacol.; vol. 68; pp. 1568-1573 (1990).
Reexmination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Second Declaration of Quraishi (May 15, 2008).
Shi, et al.; “Chronic Caffeine Alters the Density of Adenosine, Adrenergic, Cholinergic, GABA, and Serotonin Receptors and Calcium Channels in Mouse Brain”; Cellular and Molecular Neurobiology; vol. 13, No. 3:pp. 247-261 (1993).
Reexamination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Third Declaration of Poznansky (May 15, 2008).
Reexamination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Third Party Requestor's Comments (May 15, 2008).
Wang, et al.; “Parenteral Formulation of Proteins and Peptides: Stability and Stabilizers”J. Paren. Sci. Tech., vol. 42:pp. S3-S26 (1988).
Wang et al.; Polythylene Glycol-modified Chimeric TOxin Composed of Transforming Growth Factor and Psuedomonas Exotoxin; Cancer Res., vol. 53:pp. 4588-4594 (Dec. 1993).
Zimmerman et al.; “Schedule Dependency of hte Antitumor Activity and Toxicity of Polyethylene Glycol-modified Interleukin 2 in Murine Tumor Models”; Cancer Res., 49:6521-6528 (Dec. 1989).
Alberts et al, Molecular Biology of the Cell, Third Edition, New York: Garland Publishing, p. G19 (1994).
Amylin Pharmaceuticals, Inc., Form 10-Q filed Aug. 7, 2007.
Amylin Pharmaceuticals, Inc., Form 10-Q filed Nov. 6, 2007.
Barragan et al, Regulatory Peptides, 67:63-68 (1996).
Binder et al, Diabetes Care, 7:188-199 (1984).
Breton et al, Eur. J. Biochem., 231:563-569 (1995).
Broca et al., “Hydroxyisoleucine: Experimental evidence of its insulinotropic and antidiabetic properties,” Am. J. Physiol. 277:617 (1999).
Byrne et al., “Lessons from human studies with glucagon-like peptide-1: Potential of the gut hormone for clinical use,” in: Insulinotropic Gut Hormone Glucagon-Like Peptide 1, Fehmann, HC Editor, Basel, Switzerland: Karger, pp. 219-233 (1997).
BYETTA Prescribing Information.
Catalog, Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives, 1993.
Chen et al., “Tissue-specific Expression of Unique mRNAs that Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,” J. Biol. Chem. 272(7):4108-4115 (1997).
Chicchi et al. (1997) Fluorescein-Trp25S-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor. Peptides, vol. 18, pp. 319-321.
Cooper, The Cell: A Molecular Approach, ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), pp. 296-298, 648 (1997).
Creutzfeldt et al., “Glucagonstatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1(7-36) Amide in Type I Diabetic Patients,” Diabetes Care 19(6):580-586 (1996).
D'Alessio et al., “Elimination of the Action of Glucagon-Like Peptide 1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion
Prickett Kathryn S.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Connolly Bove & Lodge & Hutz LLP
Desai Anand U
Liu Samuel W
LandOfFree
Exendins and exendin agonists modified with albumin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Exendins and exendin agonists modified with albumin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendins and exendin agonists modified with albumin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4116106